London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fallen a tad but much less than the market. It is now lower than the offer price. Is it worth chancing an almost guaranteed 4p gain.
Probably more shares offering better longer term prospects currently on offer. Might have to check the dates of the offer again
longs and shorts swapping back ???
With an offer on the table just below this price, who is buying the shares
Interested parties wanting the deal to go ahead? more yes votes accumulated maybe! Markets still red on more CV19 news so just interested why purchases going ahead unless they expect a bidding war of some sort.
Pity those who bought in the 140's, no chance to get their money back even with divi's.
I think I would vote against the deal personally hoping that it could continue to grow by itself. Results looked good on first glance and I suspect more to come.
Will other come out of the woodwork with a better offer???
Always thought that indicated others interested ?
You can currently sell at a higher price than the 108p offer. No point in waiting for it.
yep, almost certainly taken down imo to make a takeover cheap.
Never understood why this share has been so beaten down until today. I bought at 100p but have been showing mostly a capital loss on it since day one. I only wish I had added more when it fell over the years. It always paid a decent divi which is why I held on but today's update surpasses even my expectations. Certainly turned the corner and then some!
See RNS which confirms above.
Putting in a couple of 1000k in here , still researching the history on why it dropped in Share Price.
Yes, I made a small purchase a couple of months ago. Fingers crossed for some well received results in March.
Thanks Beza. are you a share holder, very quite on here , just spotted the trading volume , i'm currently looking at the company accounts .
I’m not sure sharemania. Results are Tues 2nd March. Hopefully they won’t disappoint.
Large Buys 2x £8m , could coronavirus be driving the buying in this stock , please correct me if im wrong ...any share holder.?
Reassuring Results
Huntsworth shares have had a challenging year to date which in our view reflects investor concerns over the growth pause in Marketing, modest cash conversion and H1/H2 phasing. We believe that the group's interim results should provide reassurance in each of these areas. First, a combination of a robust underlying market and the benefits of the group's
strategy coming through will see LFL revenue growth in Marketing accelerate to DCe +10% in H2. Second, after the perfect storm experienced in 2018, cash conversion was 100% in 1H19 and we forecast leverage to fall to 1.6x this year followed by 1.2x in 2020. Finally, the group clearly detailed the £3.5m of investment spent in H1 and how this will drive future revenue growth. Huntsworth has made considerable strategic progress over the past year and has significantly broadened and deepened its product offering. We expect the shares will continue to re-rate as the further evidence of organic revenue growth, cash generation and the synergy benefits from M&A and launch investment come through.
• Interim results. Normalised PBT of £11.4m was ahead of DCe £10.5m.
• Revenues. Group revenues advanced +21% to £123.5m with LFL growth of +3% bolstered by acquisitions. LFL growth was +9% in Medical and Immersive, +1% in Communications and flat in Marketing.
• Adjusted Operating Profit & Margin. Group AOP rose +19% to £14.1m, with margin broadly held at 11.4%. Excluding £3.5m of staff and property investment, underlying margins rose +2.7pts to 14.2%.
• Dividend. Interim DPS was increased +7% to 0.75p, as forecast.
• Balance sheet. Net debt finished the period at £85.8m, considerably better than DCe £92.3m. The group reiterated its guidance for leverage to fall to 'around 1.5x' by the year end.
• Acquisitions. The recent acquisitions of KYNE and Creativ Ceutical are both integrating well and performing to expectations.
• Forecasts. We maintain our FY19 PBT/EPS forecasts of £40.8m/8.6p and view them as underpinned by the better than expected interim results and positive outlook comments.
Seem ok. Debt reducing and divi up and more cash in H2
Price spiked a tad on the off but as expected I suppose
Huntsworth held an impressive Capital Markets Day yesterday that
comprised detailed presentations from Group Management followed by
senior leadership from Evoke (Marketing) and MEDiSTRAVA (Medical). We
view the key points as i) the global healthcare industry continues to grow
apace with medium/long-term expansion underpinned by demographics
and supported by R&D and innovation ii) Huntsworth is uniquely
positioned to serve this marketplace and continues to target 5-7% organic
revenue growth over the next 5yrs iii) margins are sustainable in Medical
(25%+) and Marketing (23%+) with Immersive set to grow from 14% to
17% over the next 3yrs iv) acquisitions to date have delivered excellent
returns - AboveNation (IRR 28%) and The Creative Engagement Group
(20%), while the group expects strong returns at Giant (13%+) and
Navience (14%+) and v) the Group continues to focus on cash generation
and a leverage target of 'around 1.5x'. We believe the CMD highlighted
the group's robust positioning and attractive fundamentals.
• Market dynamics. Global life expectancy is increasing, with people
aged 60+ set to double to 2bn+ by 2050. This provides a strong
backdrop for the global Healthcare industry, particularly for providers
of prescription drugs that treat chronic diseases. Huntsworth has the
infrastructure to capitalise on the growth in the healthcare marketplace.
• Marketing. We forecast Marketing will generate 42% of Group
revenues and 53% of pre-central cost EBITA in 2019. Reid Connolly
(CEO of Evoke) highlighted the positioning of the enlarged Evoke
Group to offer full-service media strategy, buying, planning and adtech.
After a pause in 2018, the AGM statement indicated Marketing is well
placed to return to growth in 2H19 and into 2020 due to improved new
business and greater collaboration across business units.
• Medical. We forecast Medical will account for 14% and 20% of 2019
Group revenues and pre-central cost EBITA, respectively. The
presentation by Elaine Ferguson (CEO of MEDiSTRAVA) illustrated the
involvement of Medical through the product life cycle. Medical growth
is underpinned by an increase in early phase engagements, rise in Real
World Evidence and growth in demand for consulting projects.
staring in the green on the markets and HNT flat on the off. Well that is an improvement over 5% falls everyday....... but there is still time I here you all cry
Im not too sure either although I've not been following this too closely since getting out a while back I have been alway last week but left a "cheeky" limit order just in case they dropped further.
They did drop into the order but it looks like it wasnt that cheeky afterall as its dropped a tad further since. Not sure if its the debt levels or just not meeting "expectations" or a major seller getting out.
Hopefully this might start to settle into a more stable range for a while where we can see what the trend is likely to be. It also looks like there is some room for improvement in the figures so if that can bring the debt metrics back into line then things should start to look a lot better.
Anyway back in for the ride again and liked that the divi has increased. Maybe a bit more reading needed
I would say the drop in the sp has stemmed from targets not being met. I’ve failed to find any analyst reports so dont know their figures. Though the results looked good, most of the growth has come inorganically from acquisitions and existing business has not hit their targets partly due to exchange rates.
I have found a short report from 12th december that stated anualised revenues was due to drop 3%.
HNT has a pe ratio of 10 which is actually slightly higher than the industry average of 9.5.
The NAV price is just 48.9p.
Debt has also increased by approx double in the last year.
The large director sell last year would not have helped the sp either.
Had alert for this today but missed buying in. Soon turned around from 4.5p down.
Hmmm share price dropped off after the results. From a brief glance I can't tell why. I don't like all these restated figures. There is a mention of a cash call or share issue for up to 1-13m? I think this was for a previous acquisition.
One fund reduced after the results. Maybe director leaving not good? Where is the white elephant in the room?
like a stone? Seemed to be well on the way to a recovery but now looks in need of some CPR not to mind PR.
Yes statement suggests trading as or bettter than market expects. The net debt is a worry for me but as long as they make money that is good.
RNS today suggest Canaccord Genuity Group Inc still reducing. From 12.3% to 10.99% over the 2 holding RNS. Maybe top slicing their investment here? Someone clearly wanted shares yesterday. Also a lot of automated and or delayed buys yesterday. One assumes they were all buys.
See what happens. Could we see more bigger deals to follow? Maybe pause to let dust settle.
Statement today isn't as bad as yesterday's action suggested. I now thinking a hold rather than a sell!
I wouldn't be surprised to see further growth through acquisition, funded by share issue.